Alterity Therapeutics Lim... (ATHE)

NasdaqCM: ATHE · リアルタイム株価 · USD

4.51

-0.05 (-1.10%)

終値時点： Aug 28, 2026, 8:00 PM

4.55

+0.89%

時間外: 7:30 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-1.10% (1D)

データがありません

買気配	3.45
時価総額	81.75M
売上高（TTM）	6.64M
純利益（TTM）	-14.59M
	-0.04
	-0.58
	n/a
	-4.56
PBR（TTM）	0.04
PSR（TTM）	12.32
決算発表日	Feb 26, 2013

売気配	4.56
出来高	11,648
平均出来高（20日）	44,530
始値	4.51
前日終値	4.56
当日レンジ	4.46 - 4.83
52週レンジ	2.66 - 5.89
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ATHEについて

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy ea...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Sep 29, 2003

従業員数 9

上場取引所 NasdaqCM

ティッカー ATHE

ウェブサイト https://alteritytherapeutics.com

企業情報の全文

業績

2025年のAlterity Therapeuticsの売上高は0で、前年の0からundefined%の増加でした。利益は-12.15Mで、-36.48%の減少でした。

財務諸表

次回決算発表

Alterity Therapeutics Limitedの決算発表予定日は Feb 26, 2013, 引け後の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

2か月前 · Zacks

Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.

10か月前 · Simply Wall St.

Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability

With the business potentially at an important milestone, we thought we'd take a closer look at Alterity Therapeutics...

10か月前 · MT Newswires

Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study

Alterity Therapeutics (ATHE) said Thursday that data from a 77-patient phase 2 clinical trial of its

11か月前 · Insider Monkey

Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434

Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the Ame...

12か月前 · Simply Wall St.

We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Alterity...

Alterity Therapeutics Lim... (ATHE)

ATHEについて

業績